TICKERNERD
Menu
RIGLRIGLHealthcare · Biotechnology

RIGL Stock Forecast: Rigel Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$49
+1.52% on the day

The 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. hold a median 12-month price target of $55 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$896.4M
Ticker Nerd rank
81 / 100
Median analyst target
$55
Analysts covering
5
Revenue$78.7M−22.6% y/y
Operating income$23.6M
Net income$17.3M
Free cash flow−$39.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.7%
1M
+2.8%
YTD
+13.8%
1Y
+69.4%
From 52W high
−4.4%
From 52W low
+91.5%
$25
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RIGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rigel Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Momentum
79
Issuance
77
Growth
58
Revisions
54
Volatility
48
Size
45
Accruals
14

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RIGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RIGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26RIGLHigh $85Median $55Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $43Median $55High $85

The green dot is the last close — the median target sits +12.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Piper SandlerMaintainsNeutral$40 → $49
14 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $85
2 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.ReiteratesBuy$57
27 May 2026HC Wainwright & Co.ReiteratesBuy—
27 May 2026HC Wainwright & Co.ReiteratesBuy$57
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026CitigroupMaintainsBuy—
7 May 2026CitigroupMaintainsBuy—
5 Nov 2025Cantor FitzgeraldMaintainsNeutral—
5 Nov 2025JefferiesUpgradeBuy—
8 Oct 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025Cantor FitzgeraldMaintainsNeutral—
7 May 2025Cantor FitzgeraldMaintainsNeutral—
6 Mar 2025CitigroupMaintainsBuy—
5 Mar 2025B. Riley SecuritiesMaintainsNeutral—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RIGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RIGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Rigel Pharmaceuticals, Inc. returned +69.4% against +16.2% for the S&P 500, dividends included.

RIGL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26RIGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RIGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+14.7%
Analysts raising
1
Analysts cutting
3
Fundamentals

Rigel Pharmaceuticals, Inc. (RIGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.8×

Cheaper than 68% of US stocks

Price / sales
3.2×

Cheaper than 37% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
9.4×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
−22.6%

Higher than 11% of US stocks

Earnings growth (YoY)
−71.0%

Higher than 6% of US stocks

Gross margin
89.2%

Higher than 96% of US stocks

Operating margin
30.0%

Higher than 87% of US stocks

Net margin
116.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
126.9%

Higher than 97% of US stocks

Return on assets
15.0%

Higher than 97% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rigel Pharmaceuticals, Inc. (RIGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rigel Pharmaceuticals, Inc. has a market value of $896.4M and an enterprise value of $841.1M.

  • Revenue in the twelve months to 30 June 2026: $276.8M. The latest quarter shrank 22.6% year on year.

  • Net income over the same four quarters: $321.9M, a 116.3% net margin.

  • Diluted earnings per share, trailing twelve months: $16.32.

  • Free cash flow in the twelve months to 30 June 2026: $9.0M.

  • Shares outstanding: 18.7M.

  • Trailing P/E: 2.8×; forward P/E: 9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rigel Pharmaceuticals, Inc. employs 172 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

RIGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RIGLRigel Pharmaceuticals, Inc.$896.4M
81
MLTXMoonLake Immunotherapeutics$900.4M
16
JBIOJade Biosciences, Inc.$899.9M
26
ALMSAlumis, Inc.$886.6M
42
GLUEMonte Rosa Therapeutics, Inc.$871.8M
63
KURAKura Oncology, Inc.$933.8M
80
ANROAlto Neuroscience, Inc.$934.1M
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rigel Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RIGL news & analysis

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PRNewsWire · 2 Oct 2026neutral

Rigel Pharmaceuticals announced it has granted equity awards under its Inducement Plan, approved by the Compensation Committee of its Board of Directors, as an inducement material to employees entering employment with the company, in accordance with NASDAQ Listing Rule 5635(c)(4).

Why it matters — Rigel watchers would care because the grants reflect new executive or key employee hiring activity tied to the company's inducement equity program.

Rigel to Participate in Upcoming September Investor Conferences

PRNewsWire · 2 Sept 2026neutral

Rigel Pharmaceuticals announced that its chief financial officer, Dean Schorno, will participate in one-on-one meetings at Citi's 2026 Biopharma Back to School Conference in New York on September 9. The company also stated he will attend additional investor conferences in September.

Why it matters — Rigel watchers may be interested because the CFO's participation in investor conferences offers opportunities to communicate the company's strategy and outlook to the investment community.

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

PRNewsWire · 13 Aug 2026positive

Rigel Pharmaceuticals announced that VEPPANU (vepdegestrant) is now available by prescription in the U.S. for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The drug is described as the first and only FDA-approved PROTAC.

Why it matters — This marks the commercial availability of Rigel's first-and-only FDA-approved PROTAC for a defined breast cancer patient population, expanding the company's product portfolio.

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Seeking Alpha · 6 Aug 2026positive

Rigel Pharmaceuticals in-licensed Veppanu, a treatment for certain breast cancer patients targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 showed strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance, while the company guides $285M–$295M in 2026 revenues excluding Veppanu upside. Upcoming R289 phase 1b data and readouts from Veppanu and Rezlidhia trials are cited as additional growth catalysts.

Why it matters — RIGL watchers would care because a newly in-licensed breast cancer drug, a multi-product portfolio, and several upcoming clinical data readouts give Rigel multiple near-term growth opportunities beyond its existing commercial products.

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Seeking Alpha · 5 Aug 2026negative

Seeking Alpha downgraded Rigel Pharmaceuticals, noting that its Q2 revenue and EPS beat, driven by TAVALISSE sales, was offset by a year-over-year decline in GAVRETO and a guidance increase that came from contract revenue rather than accelerating core product sales, with net product sales guidance unchanged. VEPPANU was described as strategically sound but only incrementally valuable after upfront payments, milestones, and high royalties.

Why it matters — A RIGL watcher would care because the item argues the company's share appreciation has already occurred and that the quality of its earnings beat is weaker than headline numbers suggest.

FAQ

Frequently asked questions about RIGL stock

What is the RIGL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. have a median 12-month price target of $55, with estimates ranging from $43 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RIGL stock a buy right now?

Of the 5 analysts covering Rigel Pharmaceuticals, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rigel Pharmaceuticals, Inc. 81 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RIGL?

As at 8 Oct 2026, Rigel Pharmaceuticals, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will RIGL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks Rigel Pharmaceuticals, Inc. 81 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RIGL stock forecast for 2030?

No analyst covering Rigel Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RIGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $85 over the next 12 months.

How has RIGL stock performed over the past year?

Rigel Pharmaceuticals, Inc. returned +69.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rigel Pharmaceuticals, Inc. do?

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer.

What is the latest news on RIGL?

The most recent item we track (PRNewsWire, 2 Oct 2026): "Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)". Rigel Pharmaceuticals announced it has granted equity awards under its Inducement Plan, approved by the Compensation Committee of its Board of Directors, as an inducement material to employees entering employment with the company, in accordance with NASDAQ Listing Rule 5635(c)(4).

Company

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines. Its marketed therapies support treatment in specialized physician markets, including hematology and oncology, while its research pipeline includes additional candidates designed to modulate key signaling pathways involved in disease progression. Rigel Pharmaceuticals also works through collaboration and licensing activities that support the development and commercialization of its products. Headquartered in South San Francisco, California, and founded in 1996, Rigel Pharmaceuticals plays a focused role in the biopharmaceutical market by supplying therapies for complex conditions with limited treatment options.

CEO Mr. Raul R. Rodriguez · 172 employees · United States · https://www.rigel.com